MUSCAT – This groundbreaking treatment offers new hope for children suffering from Achondroplasia, the most common cause of congenital dwarfism.
With this advancement, the Royal Hospital becomes one of the first specialised centers in the region to offer this cutting-edge treatment – that directly targets the underlying cause of the condition – positioning Oman at the forefront of medical innovation in endocrine and genetic disorders.
Achondroplasia is a rare genetic condition that affects bone growth and results in disproportionate short stature. Voxzogo is the first medication specifically approved to treat children with achondroplasia who still have open growth plates. The drug functions by targeting overactive pathways that hinder normal bone development, effectively stimulating bone growth over time.
Read More
- Heavy rain and hail lash Oman’s Al Buraimi, triggering wadi flows
- Honourable Lady visits Omani Women’s Association in Salalah
- Oman Foreign Minister holds talks with Tunisia, Brunei on bilateral ties and global developments
- Oman, Kazakhstan review bilateral ties and regional developments
- Oman’s Health Ministry urges public to act on suspected unsafe food
The treatment is administered continuously until a child’s bone growth concludes with the closure of the growth plates.
Recognising the importance of timely treatment, the Minister of Health has expedited access to the drug. This proactive support has enabled affected children in Oman to begin treatment during the optimal developmental period, maximising the potential benefits of therapy.
